Beyond Air (XAIR) Stock Soars as Company Sells Autism Drug Platform for $32.5 Million

TLDR Beyond Air shares surged 150% after XTL Biopharmaceuticals agreed to acquire 85% of its NeuroNOS subsidiary for up to $32.5 million Deal structure includes 19.9% of XTL’s equity, $1 million cash, and milestone payments totaling $31.5 million NeuroNOS focuses on small molecule drugs targeting nitric oxide dysregulation in autism and brain cancer Two FDA [...]

The post Beyond Air (XAIR) Stock Soars as Company Sells Autism Drug Platform for $32.5 Million appeared first on Blockonomi.